<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="24689">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02785354</url>
  </required_header>
  <id_info>
    <org_study_id>1160.263</org_study_id>
    <nct_id>NCT02785354</nct_id>
  </id_info>
  <brief_title>Anticoagulants Comparative Benefit-risk Ratio in Real Life</brief_title>
  <official_title>Engel 2: REal-life aNticoaGulants Comparative bEnefit-risk in Nonvalvular Atrial fibrilLation (NVAF) in France</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The study is an analysis using the French national health insurance database, six months
      after the beginning of NOAC launch in the NVAF indication.

      The aim is to compare the one-year, two-year and three-year benefit-risk (major bleeding,
      arterial thrombotic events, myocardial infarction (MI), death) between patients starting a
      NOAC and patients starting a VKA for NVAF in 2013
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Major bleeding defined as a hospital-discharge summary with primary diagnosis of bleeding during drug (NOAC or VKA) exposure</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Arterial thrombotic event defined as a hospital-discharge summary with primary diagnosis of ischemic or undefined stroke or systemic arterial during drug (NOAC or VKA) exposure embolism</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MI defined as a hospital-discharge summary with primary diagnosis of MI or acute coronary syndrome during drug exposure</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>All-cause death defined as death (cause of death not available in the database) during drug (NOAC or VKA) exposure</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite criteria of major bleeding, arterial thrombotic events, MI or death during drug (NOAC or VKA) exposure</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>NOAC</arm_group_label>
    <description>New oral anticoagulant groups</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VKA</arm_group_label>
    <description>VKA group</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        New users of NOAC or VKA for NVAF
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

        Patients with NVAF with a first reimbursed dispensation of Pradaxa®, Xarelto®, or VKA in
        2013, with no other identified indication for anticoagulation; Without any VKA or NOAC
        (Pradaxa®, Xarelto®, or Eliquis®) reimbursed dispensation for the last 3 years before the
        first reimbursed dispensation of Pradaxa®, Xarelto®, or VKA

        Exclusion criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 25, 2016</lastchanged_date>
  <firstreceived_date>May 25, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
